A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [41] Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist
    Iijima, Toru
    Katoh, Makoto
    Takedomi, Kei
    Yamamoto, Yasuo
    Akatsuka, Hidenori
    Shirata, Naritoshi
    Nishi, Akito
    Takakuwa, Misae
    Watanabe, Yoshinori
    Munakata, Hitomi
    Koyama, Naomi
    Ikeda, Tomoko
    Iguchi, Taku
    Kato, Harutoshi
    Kikkawa, Kohei
    Kawaguchi, Takayuki
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (12) : 8127 - 8143
  • [42] Mineralocorticoid Receptor Antagonist for Renal Protection
    Ma, Terry King-Wing
    Szeto, Cheuk-Chun
    RENAL FAILURE, 2012, 34 (06) : 810 - 817
  • [43] Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects
    Garg, R.
    Kneen, L.
    Williams, G. H.
    Adler, G. K.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03) : 268 - 272
  • [44] Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction
    Toda, Kazuyoshi
    Kasama, Shu
    Toyama, Takuji
    Kasahara, Masato
    Kurabayashi, Masahiko
    JOURNAL OF NUCLEAR CARDIOLOGY, 2022, 29 (05) : 2325 - 2335
  • [45] Eplerenone: A selective aldosterone blocker
    Stier, CT
    CARDIOVASCULAR DRUG REVIEWS, 2003, 21 (03): : 169 - 184
  • [46] Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
    Erlandsson, Fredrik
    Albayaty, Muna
    Chialda, Ligia
    Ericsson, Hans
    Amilon, Carl
    Nelander, Karin
    Jansson-Lofmark, Rasmus
    Wernevik, Linda
    Kjaer, Magnus
    Bamberg, Krister
    Hartleib-Geschwindner, Judith
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (07) : 1486 - 1493
  • [47] Mineralocorticoid receptor and cardiac arrhythmia
    Gravez, Basile
    Tarjus, Antoine
    Jaisser, Frederic
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (12): : 910 - 915
  • [48] Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther, James M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (05) : 456 - 461
  • [49] Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
    Gergely, Robert
    Kovacs, Illes
    Recsan, Zsuzsanna
    Sandor, Gabor Laszlo
    Czako, Cecilia
    Nagy, Zoltan Zsolt
    Ecsedy, Monika
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [50] Mineralocorticoid receptor antagonist use following heart failure hospitalization
    Duran, Jason M.
    Gad, Shady
    Brann, Alison
    Greenberg, Barry
    ESC HEART FAILURE, 2020, 7 (02): : 482 - 492
12345